Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.

McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC, Choueiri TK.

Clin Cancer Res. 2018 May 30. doi: 10.1158/1078-0432.CCR-17-3577. [Epub ahead of print]

PMID:
29848570
2.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

PMID:
29748390
3.

Radiogenomics in renal cell carcinoma.

Alessandrino F, Shinagare AB, Bossé D, Choueiri TK, Krajewski KM.

Abdom Radiol (NY). 2018 Apr 30. doi: 10.1007/s00261-018-1624-y. [Epub ahead of print]

PMID:
29713740
4.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.

PMID:
29674707
5.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

PMID:
29437040
6.

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.

Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK.

J Immunother Cancer. 2018 Jan 22;6(1):5. doi: 10.1186/s40425-018-0315-0.

7.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, Drake CG, Ball MW, Allaf ME, Snyder A, Hellmann MD, Ho T, Motzer RJ, Signoretti S, Kaelin WG Jr, Choueiri TK, Van Allen EM.

Science. 2018 Feb 16;359(6377):801-806. doi: 10.1126/science.aan5951. Epub 2018 Jan 4.

8.

Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.

Harshman LC, Xie W, Moreira RB, Bossé D, Ruiz Ares GJ, Sweeney CJ, Choueiri TK.

Cancer. 2018 Mar 1;124(5):925-933. doi: 10.1002/cncr.31154. Epub 2017 Dec 19.

PMID:
29266178
9.

Immunotherapy in the Elderly.

Lalani AA, Bossé D, McGregor BA, Choueiri TK.

Eur Urol Focus. 2017 Oct;3(4-5):403-412. doi: 10.1016/j.euf.2017.11.008. Epub 2017 Nov 26. Review.

PMID:
29183736
10.

Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.

Sevillano E, Werner L, Bossé D, Lalani AA, Wankowicz SAM, de Velasco G, Farina M, Lundgren K, Choueiri TK, González Del Alba A, Bellmunt J.

Clin Genitourin Cancer. 2017 Dec;15(6):e1089-e1094. doi: 10.1016/j.clgc.2017.07.012. Epub 2017 Aug 2.

PMID:
28864222
11.

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.

Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK.

J Immunother Cancer. 2017 Aug 15;5(1):66. doi: 10.1186/s40425-017-0273-y.

12.

Pan-urologic cancer genomic subtypes that transcend tissue of origin.

Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ.

Nat Commun. 2017 Aug 4;8(1):199. doi: 10.1038/s41467-017-00289-x.

13.

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK.

Cancer Immunol Res. 2017 Apr;5(4):312-318. doi: 10.1158/2326-6066.CIR-16-0237. Epub 2017 Feb 28.

14.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.

Bossé D, Ng T, Ahmad C, Alfakeeh A, Alruzug I, Biagi J, Brierley J, Chaudhury P, Cleary S, Colwell B, Cripps C, Dawson LA, Dorreen M, Ferland E, Galiatsatos P, Girard S, Gray S, Halwani F, Kopek N, Mahmud A, Martel G, Robillard L, Samson B, Seal M, Siddiqui J, Sideris L, Snow S, Thirwell M, Vickers M, Goodwin R, Goel R, Hsu T, Tsvetkova E, Ward B, Asmis T.

Curr Oncol. 2016 Dec;23(6):e605-e614. doi: 10.3747/co.23.3394. Epub 2016 Dec 21.

15.

One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.

Cramer JP, Jelinek T, Paulke-Korinek M, Reisinger EC, Dieckmann S, Alberer M, Bühler S, Bosse D, Meyer S, Fragapane E, Costantini M, Pellegrini M, Lattanzi M, Dovali C.

J Travel Med. 2016 Mar 19;23(3). pii: taw011. doi: 10.1093/jtm/taw011. Print 2016 Mar.

PMID:
26994987
16.

PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium.

Bossé D, Mercer J, Raissouni S, Dennis K, Goodwin R, Jiang D, Powell E, Kumar A, Lee-Ying R, Price-Hiller J, Heng DY, Tang PA, MacLean A, Cheung WY, Vickers MM.

Clin Colorectal Cancer. 2016 Sep;15(3):243-9. doi: 10.1016/j.clcc.2016.02.003. Epub 2016 Feb 13.

PMID:
26964803
17.

Palliative chemotherapy for patients 70 years of age and older with metastatic colorectal cancer: a single-centre experience.

Bossé D, Vickers M, Lemay F, Beaudoin A.

Curr Oncol. 2015 Oct;22(5):e349-56. doi: 10.3747/co.22.2337.

18.

Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine.

Jelinek T, Cramer JP, Dieckmann S, Hatz C, Paulke-Korinek M, Alberer M, Reisinger EC, Costantini M, Gniel D, Bosse D, Lattanzi M.

Travel Med Infect Dis. 2015 May-Jun;13(3):241-50. doi: 10.1016/j.tmaid.2015.05.008. Epub 2015 May 18.

PMID:
26005163
19.

Short-Term Immunogenicity and Safety of an Accelerated Pre-Exposure Prophylaxis Regimen With Japanese Encephalitis Vaccine in Combination With a Rabies Vaccine: A Phase III, Multicenter, Observer-Blind Study.

Jelinek T, Burchard GD, Dieckmann S, Bühler S, Paulke-Korinek M, Nothdurft HD, Reisinger E, Ahmed K, Bosse D, Meyer S, Costantini M, Pellegrini M.

J Travel Med. 2015 Jul-Aug;22(4):225-31. doi: 10.1111/jtm.12210. Epub 2015 May 22.

20.

CLIA requirements for proficiency testing: the basics for laboratory professionals.

Astles JR, Stang H, Alspach T, Mitchell G, Gagnon M, Bosse D.

MLO Med Lab Obs. 2013 Sep;45(9):8-10, 12, 14-5; quiz 16. No abstract available.

PMID:
24147329
21.

Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.

Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.

PLoS One. 2013 Aug 16;8(8):e70866. doi: 10.1371/journal.pone.0070866. eCollection 2013.

22.

Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection.

Bossé D, Lemire C, Ruel J, Cantin AM, Ménard F, Valiquette L.

Infection. 2013 Apr;41(2):579-82. doi: 10.1007/s15010-012-0328-4. Epub 2012 Sep 21.

PMID:
22996384
23.

Metronomic oral cyclophosphamide in patients with advanced solid tumors.

Bojko P, Schimmel G, Bosse D, Abenhardt W.

Onkologie. 2012;35(1-2):35-8. doi: 10.1159/000336144. Epub 2012 Jan 20.

PMID:
22310343
24.

Clinician-scientist trainee: a German perspective.

Bossé D, Milger K, Morty RE.

Clin Invest Med. 2011 Dec 1;34(6):E324.

PMID:
22129920
25.

Measurement of fractional order model parameters of respiratory mechanical impedance in total liquid ventilation.

Beaulieu A, Bossé D, Micheau P, Avoine O, Praud JP, Walti H.

IEEE Trans Biomed Eng. 2012 Feb;59(2):323-31. doi: 10.1109/TBME.2011.2169257. Epub 2011 Sep 23.

PMID:
21947517
26.

Scientific overview: CSCI-CITAC annual general meeting and young investigator's forum 2010.

Berger M, Bosse D, Kuruvilla MS, Lang P, Murray JC, Nguyen LV.

Clin Invest Med. 2011 Apr 1;34(2):E105-10. Review.

PMID:
21463544
27.

Total liquid ventilation efficacy in an ovine model of severe meconium aspiration syndrome.

Avoine O, Bossé D, Beaudry B, Beaulieu A, Albadine R, Praud JP, Robert R, Micheau P, Walti H.

Crit Care Med. 2011 May;39(5):1097-103. doi: 10.1097/CCM.0b013e31820ead1a.

PMID:
21317652
28.

Experimental validation of cardiac index measurement using transpulmonary thermodilution technique in neonatal total liquid ventilation.

Bossé D, Walti H, Robert R, Lebon J, Lesur O, Praud JP, Micheau P.

ASAIO J. 2010 Nov-Dec;56(6):557-62. doi: 10.1097/MAT.0b013e3181f1cd72.

PMID:
21245803
29.

Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.

Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach PA, Lambertz H, Oruzio D, Schlag R, Weigang-Köhler K, Vehling-Kaiser U, Schulze M, Truckenbrodt J, Goebeler M, Mittermüller J, Bosse D, Szukics B, Grundeis M, Zwingers T, Giessen C, Heinemann V.

Eur J Cancer. 2011 Jan;47(2):206-14. doi: 10.1016/j.ejca.2010.09.022.

PMID:
20971632
30.

Neonatal total liquid ventilation: is low-frequency forced oscillation technique suitable for respiratory mechanics assessment?

Bossé D, Beaulieu A, Avoine O, Micheau P, Praud JP, Walti H.

J Appl Physiol (1985). 2010 Aug;109(2):501-10. doi: 10.1152/japplphysiol.01042.2009. Epub 2010 Jun 10.

31.

Scientific overview of the CSCI-CITAC 2009 conference.

Ong Tone S, Dugani S, Marshall H, Shamji MF, Murray JC, Bossé D.

Clin Invest Med. 2010 Feb 1;33(1):E69-72, E73-7. English, French.

PMID:
20144273
32.

[Treatment of chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists].

Abenhardt W, Bosse D, Böning L, Bojko P, Hitz H, Völkl S, Fromm M, Mittermüller J, Göldel N, Schick HD, Dietzfelbinger H, Hinke A.

Dtsch Med Wochenschr. 2006 Dec 1;131(48):2707-12. German.

PMID:
17123235
33.

Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.

Zuercher AW, Imboden MA, Jampen S, Bosse D, Ulrich M, Chtioui H, Lauterburg BH, Lang AB.

Clin Exp Immunol. 2006 Jan;143(1):132-8.

35.

Cellular immunity in healthy volunteers treated with an octavalent conjugate Pseudomonas aeruginosa vaccine.

Zuercher AW, Imboden MA, Jampen S, Bosse D, Ulrich M, Chtioui H, Lauterburg BH, Lang AB.

Clin Exp Immunol. 2005 Nov;142(2):381-7.

36.

High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer.

Heinemann V, Stemmler HJ, Wohlrab A, Bosse D, Losem C, Kahlert S, Rauthe G.

Cancer Chemother Pharmacol. 2006 May;57(5):640-6. Epub 2005 Sep 15.

PMID:
16163537
37.

Phase I comparability of recombinant human albumin and human serum albumin.

Bosse D, Praus M, Kiessling P, Nyman L, Andresen C, Waters J, Schindel F.

J Clin Pharmacol. 2005 Jan;45(1):57-67.

PMID:
15601806
38.

Differential expression of the LePS2 phosphatase gene family in response to phosphate availability, pathogen infection and during development.

Stenzel I, Ziethe K, Schurath J, Hertel SC, Bosse D, Köck M.

Physiol Plant. 2003 May;118(1):138-146.

PMID:
12702022
39.

Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial.

Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, Trittin A, Kern WV, Boenisch O, Bosse D, Lenz K, Ludwig WD, Hiddemann W, Siegert W, Beyer J.

Blood. 1999 Jun 1;93(11):3654-61.

40.

Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure.

Heinemann V, Bosse D, Jehn U, Debus A, Wachholz K, Forst H, Wilmanns W.

J Antimicrob Chemother. 1997 Aug;40(2):295-7.

PMID:
9302000
41.

Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.

Heinemann V, Bosse D, Jehn U, Kähny B, Wachholz K, Debus A, Scholz P, Kolb HJ, Wilmanns W.

Antimicrob Agents Chemother. 1997 Jun;41(6):1275-80.

42.

Serum pharmacology of amphotericin B applied in lipid emulsions.

Heinemann V, Kähny B, Jehn U, Mühlbayer D, Debus A, Wachholz K, Bosse D, Kolb HJ, Wilmanns W.

Antimicrob Agents Chemother. 1997 Apr;41(4):728-32.

43.
44.

The system of objective judgement analysis method: less objectivity than pretended?

Schacht P, Bosse D, Kubin R.

Pharmacoeconomics. 1995 Feb;7(2):180-2. No abstract available.

PMID:
10155304
45.
46.
47.

Inhibition of induced angiogenesis in a human microvascular endothelial cell line by ET-18-OCH3.

Candal FJ, Bosse DC, Vogler WR, Ades EW.

Cancer Chemother Pharmacol. 1994;34(2):175-8.

PMID:
7514962
48.

[Soft tissue tumors: indications and results of hyperthermia].

Issels RD, Bosse D, Starck M, Abdel-Rahman S, Jauch KW, Schildberg FW, Wilmanns W.

Chirurg. 1993 Jun;64(6):461-7. German. No abstract available.

PMID:
8359058
49.

Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study.

Issels RD, Bosse D, Abdel-Rahman S, Starck M, Panzer M, Jauch KW, Stiegler H, Berger H, Sauer H, Peter K, et al.

Cancer Chemother Pharmacol. 1993;31 Suppl 2:S233-7.

PMID:
8453705
50.

Antigen presentation by a continuous human microvascular endothelial cell line, HMEC-1, to human T cells.

Bosse D, George V, Candal FJ, Lawley TJ, Ades EW.

Pathobiology. 1993;61(3-4):236-8.

PMID:
8216847

Supplemental Content

Support Center